|
1
|
Ferrara F and Schiffer CA: Acute myeloid
leukaemia in adults. Lancet. 381:484–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Walter RB, Othus M, Burnett AK, Löwenberg
B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG,
Ravandi F, Evans A, et al: Significance of FAB subclassification of
‘acute myeloid leukemia, NOS’ in the 2008 WHO classification:
Analysis of 5848 newly diagnosed patients. Blood. 121:2424–2431.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pession A, Martino V, Tonelli R,
Beltramini C, Locatelli F, Biserni G, Franzoni M, Freccero F,
Montemurro L, Pattacini L and Paolucci G: MLL-AF9 oncogene
expression affects cell growth but not terminal differentiation and
is downregulated during monocyte-macrophage maturation in AML-M5
THP-1 cells. Oncogene. 22:8671–9676. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Basara N, Schulze A, Wedding U, Mohren M,
Gerhardt A, Junghanss C, Peter N, Dölken G, Becker C, Heyn S, et
al: Early related or unrelated haematopoietic cell transplantation
results in higher overall survival and leukaemia-free survival
compared with conventional chemotherapy in high-risk acute myeloid
leukaemia patients in first complete remission. Leukemia.
23:635–640. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Magenau J and Couriel DR: Hematopoietic
stem cell transplantation for acute myeloid leukemia: To whom,
when, and how. Curr Oncol Rep. 15:436–444. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hassan GS, Stagg J and Mourad W: Role of
CD154 in cancer pathogenesis and immunotherapy. Cancer Treat Rev.
41:431–440. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Elgueta R, Benson MJ, de Vries VC, Wasiuk
A, Guo Y and Noelle RJ: Molecular mechanism and function of
CD40/CD40L engagement in the immune system. Immunol Rev.
229:152–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Korniluk A, Kemona H and Dymicka-Piekarska
V: Multifunctional CD40L: Pro- and anti-neoplastic activity. Tumour
Biol. 35:9447–9457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li R, Chen WC, Wang WP, Tian WY and Zhang
XG: CD40 signaling activated by agonistic anti-CD40 monoclonal
antibody 5C11 has different effects on biological behavior of
gastric carcinoma cells. Immunol Lett. 131:120–125. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou Y, Ling XL, Li SW, Li XQ and Yan B:
Establishment of a human hepantoma multidrug resistant cell line in
vitro. World J Gastroenterol. 16:2291–2297. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng TT, Pan ZH, Zheng XS, et al:
Establishment and drug resistance of adriamycin-resistant breast
cancer MCF-7/Adm cell line. J Zhejiang Sci Tech Univ. 31:216–219.
2014.(In Chinese).
|
|
12
|
Li DY: Effects of overexpression of CD40L
gene on proliferation, apoptosis and drug resistance of
Kasumi-1/ADM cell line. Zunyi Med Coll. 2016.(In Chinese).
|
|
13
|
Aldinucci D, Poletto D, Nanni P, Degan M,
Rupolo M, Pinto A and Gattei V: CD40L induces proliferation,
self-renewal, rescue from apoptosis, and production of cytokines by
CD40-expressing AML blasts. Exp Hematol. 30:1283–1292. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marie JP, Huet S, Faussat AM, Perrot JY,
Chevillard S, Barbu V, Bayle C, Boutonnat J, Calvo F,
Campos-Guyotat L, et al: Multicentric evaluation of the MDR
phenotype in leukemia French network of the drug resistance
intergroup, and drug resistance network of assistance
publique-hôpitaux de Paris. Leukemia. 11:1086–1094. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun Y, Wang C, Meng Q, Liu Z, Huo X, Sun
P, Sun H, Ma X, Peng J and Liu K: Targeting P-glycoprotein and
SORCIN: Dihydromyricetin strengthens anti-proliferative efficiency
of Adriamycin via MAPK/ERK and Ca 2+ -mediated apoptosis pathways
in MCF-7/ADR and K562/ADR. J Cell Physiol. 233:3066–3079. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Styczyński J, Wysocki M, Debski R,
Balwierz W, Rokicka-Milewska R, Matysiak M, Balcerska A, Kowalczyk
J, Wachowiak J, Sońta-Jakimczyk D and Chybicka A: Cross-resistance
to five glucocorticoids in childhood acute lymphoblastic and
non-lymphoblastic leukemia samples tested by the MTT assay:
Preliminary report. Acta Biochim Pol. 49:93–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rees DC, Johnson E and Lewinson O: ABC
transporters: The power to change. Nat Rev Mol Cell Biol.
10:218–227. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Benabbou N, Mirshahi P, Bordu C, Faussat
AM, Tang R, Therwath A, Soria J, Marie JP and Mirshahi M: A subset
of bone marrow stromal cells regulate ATP-binding cassette gene
expression via insulin-like growth factor-I in a leukemia cell
line. Int J Oncol. 45:1372–1380. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fletcher JI, Williams RT, Henderson MJ,
Norris MD and Haber M: ABC transporters as mediators of drug
resistance and contributors to cancer cell biology. Drug Resist
Updat. 26:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Davidson JD, Ma L, Flagella M, Geeganage
S, Gelbert LM and Slapak CA: An increase in the expression of
ribonucleotide teductase large subunit 1 is associated with
gemcitabine resistance in non-small cell lung cancer cell lines.
Cancer Res. 64:3761–3766. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qin L, Qiu H, Zhang M, Zhang F, Yang H,
Yang L, Jia L, Qin K, Jia L, Dou X, et al: Soluble CD40 ligands
sensitize the epithelial ovarian cancer cells to cisplatin
treatment. Biomed Pharmacother. 79:166–175. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liljenfeldt L, Gkirtzimanaki K, Vyrla D,
Svensson E, Loskog AS and Eliopoulos AG: Enhanced therapeutic
anti-tumor immunity induced by co-administration of 5-fluorouracil
and adenovirus expressing CD40 ligand. Cancer Immunol Immunother.
63:273–282. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen C, Xu W and Wang CM: Combination of
celecoxib and doxorubicin increases growth inhibition and apoptosis
in acute myeloid leukemia cells. Leuk Lymphoma. 54:2517–2522. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pophali P and Litzow M: What is the best
daunorubicin dose and schedule for acute myeloid leukemia
induction? Curr Treat Options Oncol. 18:32017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chanput W, Mes JJ and Wichers HJ: THP-1
cell line: An in vitro cell model for immune modulation approach.
Int Immunopharmacol. 23:37–45. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang YK, Wang YJ, Gupta P and Chen ZS:
Multidrug resistance proteins (MRPs) and cancer therapy. AAPS J.
17:802–812. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Binkhathlan Z and Lavasanifar A:
P-glycoprotein inhibition as a therapeutic approach for overcoming
multidrug resistance in cancer: Current status and future
perspectives. Curr Cancer Drug Targets. 13:326–346. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tsuruo T, Iida H, Tsukagoshi S and Sakurai
Y: Overcoming of vincristine resistance in P388 leukemia in vivo
and in vitro through enhanced cytotoxicity of vincristine and
vinblastine by verapamil. Cancer Res. 41:1967–1972. 1981.PubMed/NCBI
|
|
29
|
Mickisch GH, Noordzij MA, vd Gaast A,
Gebreamlack P, Köhrmann KU, Mogler-Drautz E, Kupper H and Schröder
FH: Dexverapamil to modulate vinblastine resistance in metastatic
renal cell carcinoma. J Cancer Res Clin Oncol. 121 (Suppl
3):R11–R16. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thomas H and Coley HM: Overcoming
multidrug resistance in cancer: An update on the clinical strategy
of inhibiting p-glycoprotein. Cancer Control. 10:159–165. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martelli C, Coronnello M, Dei S, Manetti
D, Orlandi F, Scapecchi S, Novella Romanelli M, Salerno M, Mini E
and Teodori E: Structure-activity relationships studies in a series
of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp)
dependent multidrug resistance (MDR) inhibitors. J Med Chem.
53:1755–1762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dei S, Romanelli MN, Manetti D,
Chiaramonte N, Coronnello M, Salerno M and Teodori E: Design and
synthesis of aminoester heterodimers containing flavone or chromone
moieties as modulators of P-glycoprotein-based multidrug resistance
(MDR). Bioorg Med Chem. 26:50–64. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Styczynski J, Wysocki M, Debski R, Kurylak
A, Balwierz W, Rokicka-Milewska R, Matysiak M, Balcerska A,
Kowalczyk J, Wachowiak J, et al: The influence of intracellular
Idarubicin and daunorubicin levels on drug cytotoxicity in
childhood acute leukemia. Acta Biochim Pol. 49:99–107. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Styczynski J, Toporski J, Wysocki M,
Debski R, Chybicka A, Boruczkowski D, Wachowiak J, Wojcik B,
Kowalczyk J, Gil L, et al: Fludarabine, treosulfan and etoposide
sensitivity and the outcome of hematopoietic stem cell
transplantation in childhood acute myeloid leukemia. Anticancer
Res. 27:1547–1551. 2007.PubMed/NCBI
|
